BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biohaven Ltd.

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making materially false and misleading statements regarding its business and operations during the class period from March 24, 2023, to May 14, 2025 [1][3]. Summary by Relevant Sections Legal Action - The lawsuit is filed in the United States District Court for the District of Connecticut on behalf of all individuals and entities who purchased Biohaven securities during the specified class period [1]. - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations - The complaint alleges that Biohaven's management overstated the regulatory prospects of its drug, troriluzole, as a treatment for SCA, and the sufficiency of data submitted for regulatory approval [3]. - It is also claimed that the efficacy and clinical prospects of another drug, BHV-7000, for treating bipolar disorder were similarly overstated [3]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [3]. Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [4][7].